These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26722022)

  • 21. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
    Maguire J; Khan I; McMenemin R; O'Rourke N; McNee S; Kelly V; Peedell C; Snee M
    Eur J Cancer; 2014 Nov; 50(17):2939-49. PubMed ID: 25304298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Schild SE; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Pang HH; Wang X
    J Thorac Oncol; 2019 Feb; 14(2):298-303. PubMed ID: 30292852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis.
    Dawe DE; Christiansen D; Swaminath A; Ellis PM; Rothney J; Rabbani R; Abou-Setta AM; Zarychanski R; Mahmud SM
    Lung Cancer; 2016 Sep; 99():180-5. PubMed ID: 27565937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC).
    Panteliadou M; Giatromanolaki A; Touloupidis S; Destouni E; Tsoutsou PG; Pantelis P; Abatzoglou I; Sismanidou K; Koukourakis MI
    Urol Oncol; 2012; 30(6):813-20. PubMed ID: 21163674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
    Werner-Wasik M; Paulus R; Curran WJ; Byhardt R
    Clin Lung Cancer; 2011 Jul; 12(4):245-51. PubMed ID: 21726824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Amifostine for Cytoprotection during Radiation Therapy: A Review.
    King M; Joseph S; Albert A; Thomas TV; Nittala MR; Woods WC; Vijayakumar S; Packianathan S
    Oncology; 2020; 98(2):61-80. PubMed ID: 31846959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
    Rosenman J
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):52-8. PubMed ID: 15726524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
    Kouloulias VE; Kouvaris JR; Kokakis JD; Kostakopoulos A; Mallas E; Metafa A; Vlahos LJ
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1148-56. PubMed ID: 15234050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
    Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
    Antonadou D; Coliarakis N; Synodinou M; Athanassiou H; Kouveli A; Verigos C; Georgakopoulos G; Panoussaki K; Karageorgis P; Throuvalas N;
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):915-22. PubMed ID: 11704311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of amifostine as a radioprotector.
    Wasserman TH; Brizel DM
    Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
    Werner-Wasik M; Langer C; Movsas B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
    Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
    Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
    Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
    Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.